Literature DB >> 28612748

Novel treatment strategies in rheumatoid arthritis.

Gerd R Burmester1, Janet E Pope2.   

Abstract

New treatment strategies have substantially changed the course of rheumatoid arthritis. Many patients can achieve remission if the disease is recognised early and is treated promptly and continuously; however, some individuals do not respond adequately to treatment. Rapid diagnosis and a treat-to-target approach with tight monitoring and control, can increase the likelihood of remission in patients with rheumatoid arthritis. In this Series paper, we describe new insights into the management of rheumatoid arthritis with targeted therapy approaches using classic and novel medications, and outline the potential effects of precision medicine in this challenging disease. Articles are included that investigate the treat-to-target approach, which includes adding or de-escalating treatment. Rheumatoid arthritis treatment is impeded by delayed diagnosis, problematic access to specialists, and difficulties adhering to treat-to-target principles. Clinical management goals in rheumatoid arthritis include enabling rapid access to optimum diagnosis and care and the well informed use of multiple treatments approved for this disease.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28612748     DOI: 10.1016/S0140-6736(17)31491-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  177 in total

1.  Glucocorticoid receptor modulators CpdX and CpdX-D3 exhibit the same in vivo antiinflammatory activities as synthetic glucocorticoids.

Authors:  Guoqiang Hua; Naimah Zein; François Daubeuf; Pierre Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-21       Impact factor: 11.205

2.  Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.

Authors:  Ruihong Yu; Dawei Song; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  AAPS J       Date:  2019-07-24       Impact factor: 4.009

3.  MiR-5571-3p and miR-135b-5p, derived from analyses of microRNA profile sequencing, correlate with increased disease risk and activity of rheumatoid arthritis.

Authors:  Cailong Liu; Axiao Pan; Xiaowei Chen; Jianxin Tu; Xiaoru Xia; Li Sun
Journal:  Clin Rheumatol       Date:  2019-02-01       Impact factor: 2.980

4.  IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.

Authors:  Bo Zhang; Wei Jiang
Journal:  Inflammopharmacology       Date:  2019-08-28       Impact factor: 4.473

Review 5.  Tofacitinib: A Review in Rheumatoid Arthritis.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

Review 6.  RANKL as a therapeutic target of rheumatoid arthritis.

Authors:  Sakae Tanaka; Yoshiya Tanaka
Journal:  J Bone Miner Metab       Date:  2020-10-18       Impact factor: 2.626

7.  Efficacy and safety of jakinibs in rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Yufeng Yin; Mengru Liu; Erye Zhou; Xin Chang; Michun He; Mingjun Wang; Jian Wu
Journal:  Clin Rheumatol       Date:  2021-05-14       Impact factor: 2.980

8.  Ebosin: a potential therapeutic agent for rheumatoid arthritis and autoinflammatory syndromes.

Authors:  Yang Zhang; Lifei Wang; Yuan Li
Journal:  Cell Mol Immunol       Date:  2017-09-18       Impact factor: 11.530

9.  Diagnostic and prognostic value of anti-CarP antibodies in a sample of Egyptian rheumatoid arthritis patients.

Authors:  Sahar A Elsayed; Mohamed A Esmail; Randa M Ali; Omar M Mohafez
Journal:  Clin Rheumatol       Date:  2019-06-03       Impact factor: 2.980

Review 10.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.